STTK News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ST

Mkt Cap

$545.5M

Volume

514.18K

Next Earnings

November 5th

Loading chart

ST

STTKShattuck Labs, Inc. Common Stock

STTK

Pay with—

Available Balance0.00

ST

Mkt Cap

$555.0M

Volume

514.18K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

What Shattuck Labs Stock Topped the Market on MondayShattuck Labs (STTK) gained nearly 5% on Monday following positive analyst coverage from two firms. TD Cowen initiated a buy rating while Raymond James issued a strong buy with an $18 price target (more than double the $7.90 closing price). The optimism centers on the company's lead drug candidate SL-325, a first-in-class autoimmune and inflammatory disease treatment currently in Phase 2b clinical testing for inflammatory bowel disease, with analysts estimating a $20+ billion addressable market.The Motley Fool · Aug 24, 2026

Why Shattuck Labs Stock Flew Nearly 5% Higher on FridayShattuck Labs stock rose nearly 5% on Friday following JPMorgan Chase analyst Brian Cheng's initiation of coverage with an 'overweight' rating and $10 price target (35% upside). The bullish call was driven by positive clinical trial data for the company's lead drug candidate SL-325, a first-in-class antagonist antibody for inflammatory bowel disease, which showed a cleaner safety profile and stronger target engagement than competitors. The drug is scheduled to enter Phase 2 trials in Q3.The Motley Fool · Jul 24, 2026

Shattuck Labs, Inc. Announces Pricing of $75 Million Public OfferingShattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced the pricing of a $75 million public offering consisting of 10.88 million shares at $4.00 per share and 7.87 million pre-funded warrants at $3.9999 per warrant. The offering is expected to close on June 11, 2026, with underwriters including Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor.Benzinga · Jun 10, 2026

Shattuck Labs, Inc. Announces Pricing of $75 Million Public OfferingShattuck Labs, a clinical-stage biotechnology company developing DR3 blocking antibodies, announced the pricing of a public offering of 10.9 million shares at $4.00 per share and 7.9 million pre-funded warrants at $3.9999 per warrant, expected to raise approximately $75 million gross proceeds. The offering is expected to close on June 11, 2026, with Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor serving as joint bookrunning managers.GlobeNewswire Inc. · Jun 10, 2026

Shattuck Labs Announces Phase 1 Results for SL-325Shattuck Labs announced encouraging Phase 1 clinical trial results for SL-325, its lead DR3 blocking antibody candidate, showing a potentially best-in-mechanism immunogenicity profile with only 3.7% of participants developing antidrug antibodies, complete DR3 blockade at low doses, and a favorable safety profile. The company plans to initiate the RECEPTIVE-CD1 Phase 2b trial in Crohn's disease patients in Q3 2026, with lead bispecific candidate SL-846 expected to enter Phase 1 in H1 2027.GlobeNewswire Inc. · Jun 8, 2026

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare ConferenceShattuck Labs, a biotechnology company, announced that its CEO will present at the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025. The company's lead program, SL-325, is a potential first-in-class DR3 antagonist antibody designed to treat inflammatory and immune-mediated diseases.GlobeNewswire Inc. · Apr 2, 2025

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceShattuck Labs, a biotechnology company, announced that its CEO will present a corporate update and participate in one-on-one meetings at the upcoming J.P. Morgan Healthcare Conference.GlobeNewswire Inc. · Jan 6, 2025

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025Shattuck Labs, a biotechnology company, announced progress in the development of its potential first-in-class DR3 blocking antibody, SL-325. The company expects to initiate a phase 1 clinical trial for SL-325 in the third quarter of 2025 and is well-positioned to fund operations into 2027.GlobeNewswire Inc. · Jan 2, 2025

STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the FirmShattuck Labs, Inc. announced the discontinuation of its lead experimental therapy SL-172154 due to disappointing early-stage data, causing a significant drop in its stock price.GlobeNewswire Inc. · Oct 27, 2024

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® IndexesAUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its addition to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution. Shattuck’s addition will be effective today when the U.S. equity markets open.GlobeNewswire Inc. · Jul 1, 2024

to start trading

ST

STTKShattuck Labs, Inc. Common Stock

STTK

Pay with—

Available Balance0.00

Your PositionYou don't own any STTK yet.

Related Tickers

Earnings